Ascentage Pharma GR-ADRAAPG
13F holders, Q1 2026 (March 31)7holders −5
0new positions
5sold out
1famous investor
$23.87avg. 13F price*
At the end of Q1 2026, 7 institutions reported holding Ascentage Pharma GR-ADR (AAPG) in their 13F filings, down 5 from Q4 2025. 0 opened new positions and 5 sold out. The largest holders were Point72 Asset Management ($383K), XY Capital Ltd ($311K) and Tower Research Capital LLC (TRC) ($12K). One famous investor held it Steve Cohen (0.0% of Point72 Asset Management's portfolio).
- Company
- Ascentage Pharma GR-ADR
- CUSIP
- 04390B105
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 5 | $335K |
All 13F filers, Q4 2025 → Q1 2026: 633 shares bought and 18,163 shares sold, net −17,530 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 7 holders
| Point72 Asset Management | 0.00% | Reduce -4.0% | 16,056 | $383K |
| XY Capital Ltd | 0.34% | Reduce -4.5% | 13,014 | $311K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +125.2% | 518 | $12K |
| Morgan Stanley | 0.00% | Add +225.5% | 498 | $12K |
| UBS Group AG | 0.00% | Reduce -97.1% | 124 | $3K |
| EverSource Wealth Advisors, LLC | 0.00% | No change | 24 | $573 |
| Royal Bank of Canada | 0.00% | No change | 6 | $0 |
"% of holder's portfolio" is AAPG's weight in each manager's 13F, not the share of Ascentage Pharma GR-ADR the manager owns.